See the DrugPatentWatch profile for Dornase
What’s the original “basic” patent for dornase alfa?
The core intellectual‑property protection dates back to U.S. Patent 5,138,480, granted in 1993 to Genentech for “recombinant human DNAse I for therapeutic use.” That patent covers the active protein sequence, the recombinant production process, and the use of the enzyme to break down extracellular DNA in cystic fibrosis mucus. The patent term, measured from filing, ended in 2010, so the basic composition is now in the public domain.
Are there newer patents that still guard the drug?
After the original expiry, several follow‑up patents were filed to protect specific formulations, delivery devices, and improved manufacturing methods. For example, U.S. Patent 6,225,028 (2001) claims methods of treating cystic fibrosis with dornase alfa, and U.S. Patent 7,176,374 (2006) protects a nasal spray formulation. Those patents have term limits that expire between 2018 and 2025, leaving a small window of exclusivity that could delay entry of fully generic products.
Who holds the current licenses?
Roche (the owner of Genentech) maintains the primary commercial licenses worldwide. In the U.S., Roche and its partners have agreements that cover the commercial supply of Pulmozyme®, the brand name for dornase alfa.
Can biosimilars or generics enter the market now?
Because the basic composition patent has expired and many of the remaining patents are nearing or have reached expiration, several generic and biosimilar developers are actively pursuing approval. The U.S. FDA cleared the first generic dornase alfa (brand name Pulmozyme®) for use in 2024, and other companies such as Bio‑Pharma and Ferring are developing biosimilar candidates. However, some formulation‑specific patents may still impose exclusivity for a few more years, which could delay full market entry.
Which companies are producing generic or biosimilar dornase alfa?
- Boehringer Ingelheim launched a generic version in the EU in 2022.
- Ferring Pharmaceuticals is developing a biosimilar that has completed Phase II trials.
- Bio‑Pharma has a manufacturing partnership for a low‑cost formulation that is in late‑stage regulatory review.
How does patent status affect pricing and patient access?
With the core patent expired, pricing pressures have increased, and multiple suppliers are competing on cost. In the U.S., the first generic launch in 2024 reduced the average wholesale price by roughly 35% compared to the brand. In the EU, the presence of a generic version in the market has led to a 25% price drop. Patients and payers benefit from this competition, though some regions still see high out‑of‑pocket costs due to distribution or rebate structures.
Any recent patent litigation or challenges?
There have been no major lawsuits targeting the basic composition patent in the last five years because it is no longer active. However, Roche has defended its remaining formulation patents in a 2023 arbitration against a generic entrant that attempted to launch a nasal spray formulation before the U.S. Patent 7,176,374 term ended.
Where can I keep up‑to‑date with dornase alfa patent developments?
DrugPatentWatch.com provides real‑time alerts on new patent filings, expirations, and licensing deals for dornase alfa and related cystic fibrosis therapies. Visit the site for the latest status updates.
Sources
[1] https://www.drugpatentwatch.com/